美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

亚盛医药

15.31

+0.56003.80%

盘后：15.310.00000.00%19:56 EDT

成交量：4,679

成交额：7.13万

市值：14.29亿

市盈率：-6.58

高：15.46

开：15.19

低：15.19

收：14.75

52周最高：37.50

52周最低：14.46

股本：9,333.04万

流通股本：7,158.28万

量比：0.61

换手率：0.01%

股息：- -

股息率：- -

每股收益(TTM):-2.3260

每股收益(LYR):-1.9957

净资产收益率：-236.63%

总资产收益率：-28.04%

市净率：17.19

市盈率(LYR):-7.67

数据加载中...

总览公司新闻资讯公告

亚盛医药(06855)：受托人就2022年受限制股份单位计划购买19万股

国泰海通证券：首予亚盛医药(06855)“增持”评级目标价59.09港元

智通财经网

【直击ASCO 2026】亚盛医药MDM2-p53抑制剂APG-115儿童实体瘤数据首发，"星光计划"品种潜力初显

【直击ASCO 2026】亚盛医药耐立克®治疗CML-LBP与Ph+ BCP-ALL数据发布，有望填补急变期治疗空白

【直击ASCO 2026】亚盛医药耐立克®二线治疗CML-CP临床研究数据更新，长期疗效再获验证

达成18A“摘B”里程碑叠加重磅成果再登ASCO，亚盛医药-B(06855)全球创新价值全面释放

亚盛医药-B(06855)：受托人就2022年受限制股份单位计划购买5万股

亚盛医药获香港联交所批准从股票代码中移除"B"，6月1日起生效

亚盛医药-B(06855)：受托人就2022年受限制股份单位计划购买合共10万股

亚盛医药-B(06855)：中英文简称将不再加上标记“B”

亚盛医药-B(06855)：于2026年美国临床肿瘤学会年上公布多项临床进展

亚盛医药Bcl-2抑制剂利生妥®获 2026 版 CSCO系列指南多项重磅推荐

亚盛医药-B(06855)多项研究入选2026 ASCO

亚盛医药-B(06855)授出受限制股份单位及购股权

亚盛医药-B(06855)四项临床前进展亮相2026年美国癌症研究协会 (AACR)年会，展现多重联合治疗潜力

光鲜销售下的深层危机：亚盛医药的盈利困局与三大致命风险

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/AAPG/news?page=2"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AAPG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"亚盛医药","latestPrice":15.31,"timestamp":1791835200000,"preClose":14.75,"halted":0,"volume":4679,"hourTrading":{"tag":"盘后","latestPrice":15.31,"preClose":15.31,"latestTime":"19:56 EDT","volume":59,"amount":911.2,"timestamp":1791849397989,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.03796610169491529,"floatShares":71582800,"shares":93330405,"eps":-2.325979,"marketStatus":"已收盘","change":0.56,"latestTime":"10-12 16:00:00 EDT","open":15.19,"high":15.4551,"low":15.19,"amount":71324.495586,"amplitude":0.017973,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.325979,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1791878400000},"marketStatusCode":5,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":14.75,"preHourTrading":{"tag":"盘前","latestPrice":15.03,"preClose":14.75,"latestTime":"09:25 EDT","volume":84,"amount":1263.865932,"timestamp":1791811546156,"change":0.28,"changeRate":0.018983,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":15.31,"preClose":15.31,"latestTime":"19:56 EDT","volume":59,"amount":911.2,"timestamp":1791849397989,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.606277},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","floatShares":71582800,"roa":"-28.04%","roe":"-236.63%","lyrEps":-1.995679,"volumeRatio":0.606277,"shares":93330405,"dividePrice":0,"high":15.4551,"amplitude":0.017973,"preClose":14.75,"low":15.19,"week52Low":14.455,"pbRate":"17.19","psRate":"14.89","week52High":37.5,"institutionHeld":0,"latestPrice":15.31,"eps":-2.325979,"divideRate":0,"volume":4679,"delay":0,"ttmEps":-2.325979,"open":15.19,"prevYearClose":26.24,"prevWeekClose":14.75,"prevMonthClose":16.31,"prevQuarterClose":16.31,"fiveDayClose":14.605,"twentyDayClose":16.41,"sixtyDayClose":18.74},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AAPG\",params:#limit:5,,,undefined,":[{"date":"2026-08-19","symbol":"AAPG","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2026/06","expectedEps":-0.44,"defaultRemindTime":1787126400000,"name":null,"time":"盘前","dateTimestamp":1787112000000,"actualEps":null},{"date":"2026-03-25","symbol":"AAPG","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/12","expectedEps":null,"defaultRemindTime":1774468800000,"name":null,"time":"盘后","dateTimestamp":1774411200000,"actualEps":null},{"market":"US","date":"2025-08-20","symbol":"AAPG","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"date":"2025-03-27","symbol":"AAPG","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":null,"defaultRemindTime":1743062400000,"name":null,"time":"盘前","dateTimestamp":1743048000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AAPG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AAPG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.7143,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7143,"analysts":7,"updateTime":1781323200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AAPG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AAPG","date":"2026-10-09","current":-6.582175,"percent":0.995305,"low":-76.454813,"twenty":-35.391731,"median":-17.937257,"eighty":-9.524782,"high":-5.996207,"avg":-23.690394,"sd":16.91092,"marketCap":1322595698.71},"quantilePoints":[{"date":"2025-01-31","current":-29.751262,"twenty":-29.75286,"median":-29.751983,"eighty":-29.751262,"marketCap":1478269659.08},{"date":"2025-02-07","current":-32.664532,"twenty":-32.365221,"median":-31.242401,"eighty":-29.752127,"marketCap":1614694688.16},{"date":"2025-02-14","current":-31.1828,"twenty":-32.258438,"median":-31.212601,"eighty":-29.752938,"marketCap":1540476496.81},{"date":"2025-02-21","current":-36.382297,"twenty":-32.721933,"median":-31.802125,"eighty":-29.819279,"marketCap":1806628873.73},{"date":"2025-02-28","current":-33.43308,"twenty":-34.468465,"median":-32.375664,"eighty":-30.230932,"marketCap":1654638501.56},{"date":"2025-03-07","current":-34.452224,"twenty":-34.328072,"median":-32.712367,"eighty":-30.892818,"marketCap":1712841480.27},{"date":"2025-03-14","current":-33.065652,"twenty":-34.096417,"median":-32.760201,"eighty":-31.20664,"marketCap":1644428002.08},{"date":"2025-03-21","current":-32.72391,"twenty":-34.124503,"median":-32.947597,"eighty":-31.448698,"marketCap":1626713850.02},{"date":"2025-03-28","current":-33.955809,"twenty":-34.124503,"median":-33.010704,"eighty":-31.793328,"marketCap":1894714451.86},{"date":"2025-04-04","current":-35.921968,"twenty":-34.855052,"median":-33.21342,"eighty":-31.979778,"marketCap":2000185586.04},{"date":"2025-04-11","current":-29.511221,"twenty":-34.370118,"median":-33.010704,"eighty":-30.892818,"marketCap":1635879540.94},{"date":"2025-04-17","current":-29.520055,"twenty":-34.225935,"median":-32.760201,"eighty":-30.07059,"marketCap":1639709582.7},{"date":"2025-04-25","current":-41.553435,"twenty":-35.045268,"median":-32.920123,"eighty":-30.119556,"marketCap":2311372741.24},{"date":"2025-05-02","current":-38.492689,"twenty":-35.554336,"median":-33.187028,"eighty":-30.682879,"marketCap":2146245101.28},{"date":"2025-05-09","current":-37.35919,"twenty":-36.170996,"median":-33.361942,"eighty":-30.776099,"marketCap":2093177176.92},{"date":"2025-05-16","current":-35.007117,"twenty":-35.955639,"median":-33.43308,"eighty":-31.102567,"marketCap":1969122395.28},{"date":"2025-05-23","current":-39.338512,"twenty":-36.352488,"median":-33.608398,"eighty":-31.19472,"marketCap":2213435510.22},{"date":"2025-05-30","current":-38.856398,"twenty":-37.35919,"median":-33.992043,"eighty":-31.242401,"marketCap":2192363417.29},{"date":"2025-06-06","current":-42.814884,"twenty":-37.865895,"median":-34.141844,"eighty":-31.758144,"marketCap":2419987007.19},{"date":"2025-06-13","current":-48.171029,"twenty":-38.492689,"median":-34.477812,"eighty":-31.846105,"marketCap":2722575737.57},{"date":"2025-06-20","current":-55.929302,"twenty":-38.862859,"median":-34.635358,"eighty":-32.113451,"marketCap":3154688383.5},{"date":"2025-06-27","current":-59.787237,"twenty":-39.399619,"median":-35.123604,"eighty":-32.336589,"marketCap":3381751544.24},{"date":"2025-07-03","current":-64.068526,"twenty":-41.436089,"median":-35.258863,"eighty":-32.429915,"marketCap":3624015684.35},{"date":"2025-07-11","current":-59.084566,"twenty":-43.897892,"median":-35.501693,"eighty":-32.48435,"marketCap":3338745741.38},{"date":"2025-07-18","current":-61.880278,"twenty":-48.308604,"median":-35.791073,"eighty":-32.545465,"marketCap":3494679880.36},{"date":"2025-07-25","current":-58.315576,"twenty":-54.849764,"median":-35.921968,"eighty":-32.616809,"marketCap":3304687864.64},{"date":"2025-08-01","current":-60.559654,"twenty":-57.422661,"median":-36.233253,"eighty":-32.655768,"marketCap":3410643633.03},{"date":"2025-08-08","current":-69.260076,"twenty":-59.023969,"median":-36.597865,"eighty":-32.679287,"marketCap":3910472388.03},{"date":"2025-08-15","current":-72.346957,"twenty":-59.602544,"median":-37.391167,"eighty":-32.709995,"marketCap":4086922647.44},{"date":"2025-08-22","current":-26.724459,"twenty":-60.097702,"median":-37.493155,"eighty":-32.679287,"marketCap":4314209810.62},{"date":"2025-08-29","current":-24.396919,"twenty":-59.865528,"median":-36.699167,"eighty":-32.48435,"marketCap":3966417985.85},{"date":"2025-09-05","current":-22.946281,"twenty":-59.664109,"median":-36.382297,"eighty":-31.979778,"marketCap":3724203040.4},{"date":"2025-09-12","current":-22.941741,"twenty":-59.475774,"median":-35.943012,"eighty":-31.122625,"marketCap":3735810338.07},{"date":"2025-09-19","current":-21.785524,"twenty":-59.316014,"median":-35.857966,"eighty":-29.943039,"marketCap":3550375801.58},{"date":"2025-09-26","current":-21.102028,"twenty":-59.062646,"median":-35.66937,"eighty":-29.751262,"marketCap":3428719452.06},{"date":"2025-10-03","current":-22.266298,"twenty":-59.025902,"median":-35.30284,"eighty":-28.699054,"marketCap":3625414266.5},{"date":"2025-10-10","current":-21.050291,"twenty":-58.738293,"median":-35.189473,"eighty":-26.732175,"marketCap":3423480133.18},{"date":"2025-10-17","current":-19.80269,"twenty":-58.191808,"median":-34.731922,"eighty":-24.468638,"marketCap":3221889328.22},{"date":"2025-10-24","current":-19.801335,"twenty":-57.904825,"median":-34.477812,"eighty":-23.569995,"marketCap":3222890223.42},{"date":"2025-10-31","current":-19.321494,"twenty":-57.532716,"median":-34.141844,"eighty":-22.943557,"marketCap":3150231208.59},{"date":"2025-11-07","current":-18.112503,"twenty":-56.69325,"median":-33.992043,"eighty":-22.558349,"marketCap":2949090425.48},{"date":"2025-11-14","current":-19.583345,"twenty":-55.920234,"median":-33.485756,"eighty":-22.342071,"marketCap":3199584585.23},{"date":"2025-11-21","current":-17.547753,"twenty":-55.765092,"median":-33.408485,"eighty":-22.122489,"marketCap":2860955000.96},{"date":"2025-11-28","current":-18.539078,"twenty":-55.318442,"median":-33.361942,"eighty":-21.796498,"marketCap":3034915066.08},{"date":"2025-12-05","current":-18.33416,"twenty":-53.27811,"median":-33.187028,"eighty":-21.590149,"marketCap":3005486168.49},{"date":"2025-12-12","current":-17.062052,"twenty":-48.796704,"median":-32.920123,"eighty":-21.073758,"marketCap":2802301628.68},{"date":"2025-12-19","current":-16.188794,"twenty":-48.517949,"median":-32.72391,"eighty":-20.125041,"marketCap":2665447409.6},{"date":"2025-12-26","current":-15.347054,"twenty":-48.514967,"median":-32.664532,"eighty":-19.801335,"marketCap":2537308174.25},{"date":"2026-01-02","current":-14.520508,"twenty":-48.239817,"median":-32.57809,"eighty":-19.656119,"marketCap":2406972911.39},{"date":"2026-01-09","current":-15.636938,"twenty":-46.480698,"median":-32.420873,"eighty":-19.300607,"marketCap":2595562368.02},{"date":"2026-01-16","current":-14.792082,"twenty":-45.997596,"median":-31.846105,"eighty":-19.073232,"marketCap":2461528990.12},{"date":"2026-01-23","current":-14.451393,"twenty":-45.706429,"median":-31.242401,"eighty":-18.892753,"marketCap":2402559084.95},{"date":"2026-01-30","current":-13.594278,"twenty":-43.897892,"median":-30.891003,"eighty":-18.486342,"marketCap":2268064814.82},{"date":"2026-02-06","current":-13.215954,"twenty":-42.7913,"median":-29.979764,"eighty":-18.329609,"marketCap":2208187061.91},{"date":"2026-02-13","current":-13.314281,"twenty":-42.590497,"median":-29.752899,"eighty":-18.136415,"marketCap":2236446544.83},{"date":"2026-02-20","current":-13.322258,"twenty":-42.10164,"median":-29.751262,"eighty":-17.934704,"marketCap":2235292402.77},{"date":"2026-02-27","current":-13.022247,"twenty":-41.475205,"median":-29.511221,"eighty":-17.157024,"marketCap":2206480506.48},{"date":"2026-03-06","current":-12.669019,"twenty":-41.161756,"median":-28.176938,"eighty":-16.734267,"marketCap":2131116747.44},{"date":"2026-03-13","current":-12.688953,"twenty":-40.378179,"median":-26.74375,"eighty":-16.137082,"marketCap":2141399622.46},{"date":"2026-03-20","current":-11.937263,"twenty":-39.521832,"median":-25.944924,"eighty":-15.566094,"marketCap":2005434649.33},{"date":"2026-03-27","current":-12.020857,"twenty":-39.289753,"median":-24.396919,"eighty":-15.439715,"marketCap":2161491459.44},{"date":"2026-04-02","current":-13.548587,"twenty":-39.152841,"median":-23.731199,"eighty":-15.186721,"marketCap":2444436047.79},{"date":"2026-04-10","current":-12.693217,"twenty":-38.895939,"median":-23.387346,"eighty":-14.745986,"marketCap":2308441702.51},{"date":"2026-04-17","current":-13.620079,"twenty":-38.882244,"median":-22.946281,"eighty":-14.465216,"marketCap":2481253103.51},{"date":"2026-04-24","current":-12.083101,"twenty":-38.84865,"median":-22.780777,"eighty":-14.008358,"marketCap":2199221373.05},{"date":"2026-05-01","current":-11.527627,"twenty":-38.758432,"median":-22.499202,"eighty":-13.791914,"marketCap":2098243441.9},{"date":"2026-05-08","current":-10.968155,"twenty":-38.515761,"median":-22.389807,"eighty":-13.684651,"marketCap":2004129088.99},{"date":"2026-05-15","current":-10.082774,"twenty":-38.444183,"median":-22.266298,"eighty":-13.539734,"marketCap":1846775928.57},{"date":"2026-05-22","current":-10.707594,"twenty":-38.225934,"median":-22.137659,"eighty":-13.395768,"marketCap":1956144727.44},{"date":"2026-05-29","current":-10.055476,"twenty":-38.129026,"median":-21.923528,"eighty":-13.314281,"marketCap":1843351578.24},{"date":"2026-06-05","current":-8.909894,"twenty":-37.937734,"median":-21.785524,"eighty":-13.216389,"marketCap":1635661877.38},{"date":"2026-06-12","current":-8.93641,"twenty":-37.865895,"median":-21.603031,"eighty":-13.157057,"marketCap":1639076784.73},{"date":"2026-06-18","current":-8.353042,"twenty":-37.752402,"median":-21.278471,"eighty":-13.101714,"marketCap":1535636323.4},{"date":"2026-06-26","current":-7.824164,"twenty":-37.62092,"median":-21.066691,"eighty":-13.023474,"marketCap":1430786980.62},{"date":"2026-07-02","current":-8.952074,"twenty":-37.472757,"median":-20.67449,"eighty":-12.989985,"marketCap":1637864621.41},{"date":"2026-07-10","current":-9.338033,"twenty":-37.371981,"median":-19.946515,"eighty":-12.776282,"marketCap":1707700089.2},{"date":"2026-07-17","current":-9.151372,"twenty":-36.963176,"median":-19.801335,"eighty":-12.672971,"marketCap":1678950333.06},{"date":"2026-07-24","current":-9.04646,"twenty":-36.577605,"median":-19.676085,"eighty":-12.361815,"marketCap":1659751775.25},{"date":"2026-07-31","current":-8.626077,"twenty":-36.450857,"median":-19.539859,"eighty":-12.179575,"marketCap":1585151449.4},{"date":"2026-08-07","current":-9.281807,"twenty":-36.322679,"median":-19.321494,"eighty":-11.987055,"marketCap":1708580872.07},{"date":"2026-08-14","current":-9.158138,"twenty":-36.125575,"median":-19.172925,"eighty":-11.879713,"marketCap":1687515849.52},{"date":"2026-08-21","current":-7.057849,"twenty":-35.947221,"median":-19.05933,"eighty":-11.591162,"marketCap":1541157743.83},{"date":"2026-08-28","current":-7.528669,"twenty":-35.921968,"median":-18.891573,"eighty":-11.215925,"marketCap":1645140637.76},{"date":"2026-09-04","current":-7.512769,"twenty":-35.896367,"median":-18.539078,"eighty":-10.909833,"marketCap":1642057095.97},{"date":"2026-09-11","current":-6.726657,"twenty":-35.844587,"median":-18.43689,"eighty":-10.516338,"marketCap":1472033722.18},{"date":"2026-09-18","current":-6.328251,"twenty":-35.78272,"median":-18.34244,"eighty":-10.147967,"marketCap":1385839347.04},{"date":"2026-09-25","current":-6.198771,"twenty":-35.717333,"median":-18.302386,"eighty":-9.993282,"marketCap":1355442980.28},{"date":"2026-10-02","current":-6.256521,"twenty":-35.554336,"median":-18.13243,"eighty":-9.623881,"marketCap":1368865778.06},{"date":"2026-10-09","current":-6.039007,"twenty":-35.391731,"median":-17.937257,"eighty":-9.524782,"marketCap":1322595698.71}],"updateTime":1791854721102},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AAPG\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2642426730","title":"亚盛医药(06855)：受托人就2022年受限制股份单位计划购买19万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642426730","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642426730?lang=zh_cn&edition=fundamental","pubTime":"2026-06-10 20:54","pubTimestamp":1781096082,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药(06855)发布公告，于2026年6月10日，受托人就2022年受限制股份单位计划目的于场内购买合共19万股现有股份以在归属后满足受限制股份单位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452805.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","BK4139","AAPG","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640937177","title":"国泰海通证券：首予亚盛医药(06855)“增持”评级 目标价59.09港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640937177","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640937177?lang=zh_cn&edition=fundamental","pubTime":"2026-06-01 16:58","pubTimestamp":1780304322,"startTime":"0","endTime":"0","summary":"2025年，公司商业化成果显著，实现总收益5.74亿元，不考虑武田付款同比增长90%，其中，奥雷巴替尼实现收入4.35亿元，利沙托克拉实现7085万元，合计5.06亿元。2025年末现金余额为24.7亿元，现金储备稳健，可以支撑到2027年。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260601/20260601165411_97234.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260601/20260601165411_97234.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["EWH","AAPG","02611","06855","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640982786","title":"【直击ASCO 2026】亚盛医药MDM2-p53抑制剂APG-115儿童实体瘤数据首发，\"星光计划\"品种潜力初显","url":"https://stock-news.laohu8.com/highlight/detail?id=2640982786","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640982786?lang=zh_cn&edition=fundamental","pubTime":"2026-06-01 09:40","pubTimestamp":1780278000,"startTime":"0","endTime":"0","summary":"此次快速口头报告的研究进展初步展现了APG-115在儿童相关实体瘤患者中的抗肿瘤活性和安全性。此次在ASCO 展示的数据证实，APG-115 单药及联合利沙托克拉展现出良好耐受性与显著抗肿瘤活性，尤其是CR 病例令人鼓舞。此次在ASCO展示的研究为APG-115治疗儿童实体瘤患者的数据首次亮相，初步展现的疗效和耐受性令人鼓舞。值得一提的是，APG-115此前已获CDE纳入'星光计划'，拟开发用于多种儿童实体瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/4972105_ZH72105_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4972105_ZH72105_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["APG","BK4139","06855","LU2125909916.SGD","LU1923622291.USD","BK1161","AAPG","BK4129","LU2125909759.SGD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640982781","title":"【直击ASCO 2026】亚盛医药耐立克®治疗CML-LBP与Ph+ BCP-ALL数据发布，有望填补急变期治疗空白","url":"https://stock-news.laohu8.com/highlight/detail?id=2640982781","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640982781?lang=zh_cn&edition=fundamental","pubTime":"2026-06-01 09:02","pubTimestamp":1780275720,"startTime":"0","endTime":"0","summary":"\" 亚盛医药首席医学官翟一帆博士表示：\"此次快速口头报告的研究首次在国际患者中验证了耐立克联合贝林妥欧单抗针对CML-LBP与R/R Ph+ BCP-ALL的治疗潜力。此次展示的数据非常令人鼓舞，有望填补急变期治疗的长期空白。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/4972102_ZH72102_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4972102_ZH72102_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","LU2355687059.USD","AAPG","LU0985320562.USD","BK4533","LU1571399168.USD","06855","LU1699723380.USD","ALL","BK4585","BK4107","BK1574","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640784982","title":"【直击ASCO 2026】亚盛医药耐立克®二线治疗CML-CP临床研究数据更新，长期疗效再获验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2640784982","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640784982?lang=zh_cn&edition=fundamental","pubTime":"2026-06-01 08:59","pubTimestamp":1780275540,"startTime":"0","endTime":"0","summary":"今年是亚盛医药连续第九年亮相ASCO年会，此次公司三个重点品种共有六项研究入选，其中三项获快速口头报告。此外，亚盛医药已经与跨国制药企业武田就耐立克签署了一项独家选择权事宜。在既往接受二代TKI治疗的患者中仍保持较高疗效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/4972100_ZH72100_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4972100_ZH72100_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["CP","LU1989763690.USD","BK1574","LU1261432733.SGD","AAPG","BK4588","BK1161","BK4585","BK4016","BK4139","06855","LU1989763427.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639645908","title":"达成18A“摘B”里程碑叠加重磅成果再登ASCO，亚盛医药-B(06855)全球创新价值全面释放","url":"https://stock-news.laohu8.com/highlight/detail?id=2639645908","media":"智通财经","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639645908?lang=zh_cn&edition=fundamental","pubTime":"2026-05-29 11:23","pubTimestamp":1780025014,"startTime":"0","endTime":"0","summary":"财报显示，2025年，亚盛医药实现营业收入5.74亿元，且截至目前市值已超过百亿港元。而耐立克和利生妥两大十亿美元分子相继获批上市并在终端市场实现快速放量，便是亚盛医药能够顺利达成18A“摘B”里程碑的重要原因。智通财经APP了解到，亚盛医药今年六项重磅研究成果入选2026年ASCO年会。以上无疑都将成为亚盛医药年内的重要催化。近年来已有10数家18A企业顺利“摘B”，并在“摘B”后实现了可观的估值增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447587.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"达成18A“摘B”里程碑叠加重磅成果再登ASCO，亚盛医药-B(06855)全球创新价值全面释放","news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","AAPG","BK1161","BK4139","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638992766","title":"亚盛医药-B(06855)：受托人就2022年受限制股份单位计划购买5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2638992766","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638992766?lang=zh_cn&edition=fundamental","pubTime":"2026-05-28 21:58","pubTimestamp":1779976713,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B(06855)发布公告，于2026年5月28日，受托人就2022年受限制股份单位计划目的于场内购买合共5万股现有股份以在归属后满足受限制股份单位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447445.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","BK4139","BK1161","BK1574","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638651100","title":"亚盛医药获香港联交所批准从股票代码中移除\"B\"，6月1日起生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2638651100","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638651100?lang=zh_cn&edition=fundamental","pubTime":"2026-05-28 11:06","pubTimestamp":1779937560,"startTime":"0","endTime":"0","summary":"美国马里兰州罗克维尔市和中国苏州2026年5月28日 /美通社/ --致力于在肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药宣布，因公司已符合香港联交所上市规则第8.05条的市值/收益要求，日前已获得香港联交所批准，将于2026年6月1日起正式将\"B\"标记从股票代码中移除。亚盛医药于2019年10月28日通过18A规则在香港联交所主板挂牌上市，后陆续纳入深港通和沪港通股票名单。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/4969934_ZH69934_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4969934_ZH69934_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","AAPG","06855","BK1574","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638081685","title":"亚盛医药-B(06855)：受托人就2022年受限制股份单位计划购买合共10万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2638081685","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638081685?lang=zh_cn&edition=fundamental","pubTime":"2026-05-27 21:58","pubTimestamp":1779890296,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B(06855)发布公告，于2026年5月27日，受托人就2022年受限制股份单位计划目的于场内购买合共10万股现有股份以在归属后满足受限制股份单位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446882.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","BK1161","BK1574","BK4139","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638501850","title":"亚盛医药-B(06855)：中英文简称将不再加上标记“B”","url":"https://stock-news.laohu8.com/highlight/detail?id=2638501850","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638501850?lang=zh_cn&edition=fundamental","pubTime":"2026-05-27 18:31","pubTimestamp":1779877916,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B(06855)发布公告，由于相关规则不适用，公司的中英文简称自2026年6月1日起将不再加上标记“B”。公司的股份将以新英文股份简称“ASCENTAGE”及中文股份简称“亚盛医药”在联交所买卖。公司的股份代号维持不变，仍为“6855”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446700.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","AAPG","BK4139","BK1161","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637363327","title":"亚盛医药-B(06855)：于2026年美国临床肿瘤学会年上公布多项临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2637363327","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637363327?lang=zh_cn&edition=fundamental","pubTime":"2026-05-22 07:46","pubTimestamp":1779407170,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，本公司六项入选2026年美国临床肿瘤学会年会的临床研究的摘要已于ASCO官网公布。本届ASCO年会将于2026年5月29日至2026年6月2日在芝加哥伊利诺伊州McCormick会议中心以线上线下结合的形式举办。该方案安全性可控，在儿童相关实体瘤中初步展现抗肿瘤活性，值得进一步研究。主要终点均为24周的主要分子学反应率。研究计划纳入约440例患者，在18个国家126个中心开展，目前正在招募中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444811.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","AAPG","06855","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630353293","title":"亚盛医药Bcl-2抑制剂利生妥®获 2026 版 CSCO系列指南多项重磅推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2630353293","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630353293?lang=zh_cn&edition=fundamental","pubTime":"2026-04-27 09:49","pubTimestamp":1777254540,"startTime":"0","endTime":"0","summary":"利沙托克拉是亚盛医药自主研发的新型口服Bcl-2选择性抑制剂，通过选择性抑制Bcl-2蛋白，恢复癌细胞的正常凋亡过程，从而达到治疗肿瘤的目的。作为中国首个获批上市的国产原创Bcl-2抑制剂，此次利沙托克拉在 2026 版CSCO系列指南中的全面落地，充分展现了该产品在多个血液肿瘤领域的卓越临床价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/4943806_ZH43806_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4943806_ZH43806_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["CSCS","LU2237443622.USD","IE00BVYPNV92.GBP","IE000M9KFDE8.USD","LU2237443895.HKD","LU0203345920.USD","LU2102340556.USD","CSCO","BK4588","SG9999001424.SGD","SG9999015945.SGD","LU1162221912.USD","IE00B42XCP33.USD","LU2237443465.HKD","06855","CSCL","LU1778281490.HKD","LU0823417653.USD","IE00B3PB1722.GBP","LU1066051498.USD","LU1883839398.USD","LU1674673691.USD","LU2286300806.USD","BK4533","LU1066051811.HKD","SG9999002224.SGD","LU2247934214.USD","BK4585","BK1574","LU0942090050.USD","BK4560","LU0348723411.USD","BK4020","LU1059921491.USD","LU0234572021.USD","LU0234570918.USD","LU0889566641.SGD","BK1161","AAPG","IE00BSNM7G36.USD","LU0868494708.USD","LU1571399168.USD","LU1244550577.SGD","BK4579","LU1032955483.USD","LU1267930813.SGD","LU0203347892.USD","LU1066053197.SGD","SG9999015986.USD","LU1221951129.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629069553","title":"亚盛医药-B(06855)多项研究入选2026 ASCO","url":"https://stock-news.laohu8.com/highlight/detail?id=2629069553","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629069553?lang=zh_cn&edition=fundamental","pubTime":"2026-04-22 07:05","pubTimestamp":1776812706,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B(06855)公布，公司三个重点品种的六项临床研究入选2026年美国临床肿瘤学会(ASCO)年会，其中三项获快速口头报告，三项获壁报展示。这三个重点品种分别为中国首个获批上市的第三代BCR-ABL抑制剂奥雷巴替尼(商品名：耐立克®)、中国首个获批上市的国产塬创Bcl-2选择性抑制剂利沙托克拉(商品名：利生妥®)和MDM2-p53抑制剂Alrizomadlin(APG-115)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","AAPG","06855","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628721474","title":"亚盛医药-B(06855)授出受限制股份单位及购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2628721474","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628721474?lang=zh_cn&edition=fundamental","pubTime":"2026-04-20 22:42","pubTimestamp":1776696140,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，截至本公告日期，已向2022年受限制股份单位计划的3名选定人士授出69.63万份受限制股份单位，相当于 69.63万股股份，其中向本公司执行董事兼首席执行官杨大俊博士(杨博士)授出39.38万份受限制股份单位;向本公司首席医学官兼主要股东翟一帆博士(翟博士)授出28.39万份受限制股份单位;及向本公司1名高级管理人员授出1.86万份受限制股份单位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430985.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","06855","BK1161","BK4139","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628791678","title":"亚盛医药-B(06855)四项临床前进展亮相2026年美国癌症研究协会 (AACR)年会，展现多重联合治疗潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2628791678","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628791678?lang=zh_cn&edition=fundamental","pubTime":"2026-04-20 07:14","pubTimestamp":1776640456,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 公布，公司将在2026年美国癌症研究协会年会上以壁报形式公布四项临床前研究成果。该会议于2026年4 月17日至2026年4月22日在美国加州圣地亚哥举行。本次壁报涉及公司三个品种，包括：原创1类新药BCR-ABL抑制剂奥雷巴替尼、FAK/ALK/ROS1三联酪氨酸激酶抑制剂APG-2449、以及PRC2/EED抑制剂APG-5918。此外，公司针对BRAF突变肿瘤开展的APG-2449 研究、以及针对小细胞肺癌开展的APG-5918研究，凸显了公司聚焦攻克耐药机制、探索联合用药策略的战略方向。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430403.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","06855","BK4139","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628208448","title":"光鲜销售下的深层危机：亚盛医药的盈利困局与三大致命风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2628208448","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628208448?lang=zh_cn&edition=fundamental","pubTime":"2026-04-17 19:01","pubTimestamp":1776423660,"startTime":"0","endTime":"0","summary":"在国产创新药赛道上，亚盛医药曾是最耀眼的明星之一。然而，其近日披露的2025年年报，却揭示了一家明星企业“销量猛增、亏损加剧”的典型困境。　　表面上看，核心产品耐立克销售额突破4.35亿元，整体商业化收入同比增长90%，似乎交出了一份不错的成绩单。但细究之下，公司全年净亏损高达12.43亿元，同比扩大206.4%，创下历史新高。这背后，隐藏着三大不可忽视的结构性风险。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-04-17/doc-inhuveqy6429410.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","AAPG"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":36,"code":"91000000","status":"200"}]}}